TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The phase III SYNCHRONIZE-2 trial found that survodutide, an investigational glucagon/GLP-1 agonist, reduced body weight and HbA1c in adults with obesity and type 2 diabetes over 76 weeks. Gastrointestinal side effects were common, and 18% of participants in each dose group stopped the trial regimen because of those events, compared with 1.2% on placebo.
The investigational drug survodutide reduced body weight and HbA1c in adults with obesity and type 2 diabetes in the 76-week phase III SYNCHRONIZE-2 trial, but gastrointestinal side effects led substantially more participants to stop treatment than placebo. The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan and published in the New England Journal of Medicine, point to potential metabolic benefits while leaving tolerability as a major concern.
Participants receiving weekly injections of 3.6 mg survodutide lost an average of 8.2% of their body weight by week 76; those assigned to 6 mg lost 9.8%. The placebo group lost an average of 3.9%. At least 5% weight loss was recorded in 57.6% of the lower-dose group, 64.5% of the higher-dose group and 35.1% of the placebo group. The trial report said both active-treatment comparisons with placebo were statistically significant.
Average HbA1c, a measure of blood sugar over time, was 7.4% at baseline. By the end of the study, it had fallen by 0.9 percentage points with 3.6 mg and 0.8 points with 6 mg, compared with a 0.2-point reduction on placebo. Presenting the findings, Sean Wharton, MD, of Wharton Medical Clinic Weight and Diabetes Management in Hamilton, Ontario, said survodutide was also associated with improvements in systolic blood pressure, waist circumference and lipids.
Gastrointestinal adverse events affected 73% to 78% of participants receiving survodutide, compared with 38.6% on placebo. Most events were described as mild to moderate and transient, but gastrointestinal problems prompted 18% of participants in each survodutide group to discontinue the trial regimen, versus 1.2% on placebo. Across all adverse events, treatment discontinuation occurred in 26% of each survodutide group and 9% of the placebo group.
Benefits Must Be Weighed Against Dropouts
The results matter because weight reduction and improved blood-sugar measures could address two connected health concerns for people living with type 2 diabetes and obesity. The trial found greater average weight loss and HbA1c reductions with survodutide than with placebo, although the size of the effect varied by outcome and dose. The report does not establish how these changes will translate into long-term health outcomes for this population.
The high rate of side effects leading to treatment discontinuation complicates the potential benefit. A drug’s measured effect in a trial may be harder for patients to realize if they cannot tolerate the regimen. Andreas Birkenfeld, MD, PhD, of University Hospital Tübingen, said the results did not show an additional safety signal beyond concerns already known, while also pointing to the markedly higher gastrointestinal discontinuation rate compared with some other agents. These findings make tolerability and dose adjustment relevant questions for future studies and any later assessment of the medicine.
Comparisons with other drugs require care: figures cited in the report came from separate studies, not a direct head-to-head comparison. The trial investigators wrote that the 9.8% weight loss in the higher-dose group was of a magnitude associated with cardiovascular benefits and fewer metabolic and mechanical complications, as well as improved quality of life. Those are the authors’ interpretation of the amount of weight lost, not outcomes established by this trial.
Products Worth Considering
Dyson Ball Animal 3 Corded Upright Vacuum
Levoit Vital 100S-P Air Purifier
Dyson V8 Cyclone Cordless Vacuum
As an affiliate, we earn on qualifying purchases.
A Diabetes-Focused Survodutide Trial
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist; it is not a GIP receptor agonist. The source report issued a correction after an earlier version misidentified the drug. SYNCHRONIZE-2 was a multinational, double-blind trial with 752 participants: 250 assigned to 3.6 mg, 251 to 6 mg and 251 to placebo. Participants had type 2 diabetes and a body mass index of at least 27. They received a once-weekly injection, and the study ran from November 2023 through March 2026.
Participants had a mean age of 55.7 years and a mean BMI of 36.5; 49.3% were men. The investigators said weight loss was below the maximum 13% reported in SYNCHRONIZE-1, an earlier study that excluded people with diabetes. The populations and study conditions differed, so the results should not be treated as a direct comparison between the trials.
The SYNCHRONIZE-2 study also excluded people taking insulin. Most participants had relatively well-controlled blood sugar at the outset while using oral glucose-lowering medicines. That design limits how confidently the results can be applied to the broader population of people with type 2 diabetes, particularly those who use insulin or have different levels of glycemic control.
“Survodutide was associated with improvements in other cardiometabolic parameters, including systolic blood pressure, waist circumference, and lipids.”
— Sean Wharton, MD, presenting the trial findings
Who Can Apply These Results?
The findings do not show how survodutide would perform in patients taking insulin, because they were excluded. Since most participants began with relatively well-controlled blood sugar while taking oral medicines, effects in people with more difficult-to-control diabetes remain uncertain. The report also does not establish whether the weight and HbA1c changes will persist after treatment ends or reduce cardiovascular events in this trial population.
It is not yet clear whether a more flexible titration schedule will reduce nausea and other gastrointestinal problems or lower discontinuation. The study showed that most reported gastrointestinal events were mild to moderate and transient, but it also recorded substantial treatment stopping related to those events. The reasons for discontinuation and the rate differences between treatment groups are reported; how best to prevent those outcomes remains an open question.
Survodutide’s reported weight-loss and HbA1c figures also should not be read as proof that it is less or more effective than semaglutide, tirzepatide or retatrutide. The figures cited for those medicines were drawn from different trials, with differing participants and study methods. No direct comparison was reported here.
Flexible Dosing and Outcomes Trials
Boehringer Ingelheim says future survodutide trials will test more flexible, patient-centered dose titration intended to improve tolerability. The available report does not provide a schedule or results for those studies, so whether a different escalation approach will reduce gastrointestinal events or treatment discontinuation is not yet known.
Data from a separate cardiovascular outcomes trial are expected later this year, according to the source report. Those results may add evidence about longer-term cardiovascular outcomes, but they will not by themselves resolve how well the SYNCHRONIZE-2 results apply to insulin users or people with less-controlled diabetes. For now, the phase III findings establish both a measurable weight and HbA1c benefit against placebo and a tolerability issue that future research will need to address.
Key Questions
What is survodutide?
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist being studied for metabolic conditions. The source report corrected an earlier description that incorrectly called it a GIP receptor agonist.
How much weight did participants lose?
By week 76, average weight loss was 8.2% with 3.6 mg and 9.8% with 6 mg, compared with 3.9% on placebo. These are results from SYNCHRONIZE-2, not a direct comparison with other medicines.
What were the main tolerability concerns?
Gastrointestinal events occurred in 73% to 78% of participants on survodutide and 38.6% on placebo. Such events led 18% in each survodutide group to stop the trial regimen, compared with 1.2% on placebo.
Do the findings apply to everyone with type 2 diabetes?
Not necessarily. The trial excluded people taking insulin, and most participants had relatively well-controlled blood sugar while using oral medicines. The results may not represent all people with type 2 diabetes and obesity.
What is expected next?
The developer says future trials will test more flexible dose titration. The source report also says data from a cardiovascular outcomes trial are expected later this year; the timing and findings of those data remain pending.
Source: rss
